Table 1 Baseline and treatment characteristics of 88 patients

Number of patients

88

Age (years), median (range)

63.5 (39–81)

Gender

 Male

64 (73)

 Female

24 (27)

Histology, N (%)

 Renal cell carcinoma

38 (43)

 Prostate cancer

26 (30)

 Urothelial cancer

24 (27)

Cancer Stage (UICC, 8th ed.), N (%)

 I

16 (18)

 II

16 (18)

 III

20 (23)

 IV

36 (41)

Distant metastases, N (%)

 No

52 (59)

 Yes:

36 (41)

 Lung

27 (31)

 Liver

14 (16)

 Lymph nodes

13 (15)

 Bone

10 (11)

 Pleura

5 (6)

 Brain

1 (1)

 Pancreas

1 (1)

Surgical treatment at the time of COVID-19

 Before surgery, N (%)

1 (1)

 After surgery, N (%)

46 (52)

 Time from performed surgery to COVID-19, median (days, range)

6.5 (2–14)

Radiation therapy at the time of COVID-19, N (%)

15 (17)

Systemic therapy at the time of COVID-19 infection, N (%)

 Patients during first-line therapy

18 (21)

 Patients during subsequent therapy

4 (5)

 Checkpoint inhibitors

8 (9)

 Targeted therapy

7 (8)

 Combination of checkpoint inhibitors and

1 (1)

Targeted agent

 Chemotherapy/gonadotropin releasing hormone analogs

6 (27)

 Not started (in case of initial planning)

14 (16)

 Interrupted (if the patient was on therapy)

19 (9)

 Continued

3 (3)